Document is current
Any future updates will be listed below
-
Authors
Ehinger, Yann https://orcid.org/0000-0001-9314-6575
Zhang, Ziyang https://orcid.org/0000-0003-0541-7211
Phamluong, Khanhky
Soneja, Drishti
Shokat, Kevan M. https://orcid.org/0000-0001-8590-7741
Ron, Dorit https://orcid.org/0000-0001-5161-967X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (R01 AA027474)
Damon Runyon Cancer Research Foundation (DRG-2281-17)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA221969)
Michael J. Fox Foundation for Parkinson’s Research (P0536220)
- License Information
-
More Information
Article History
Received: 12 November 2020
Accepted: 23 June 2021
First Online: 27 July 2021
Competing interests
: K.M.S. and Z.Z. are co-inventors on patent applications covering RapaBlock owned by UCSF. K.M.S. is an inventor on patents covering RapaLink-1 owned by UCSF and licensed to Revolution Medicines. K.M.S. receives monetary and stock compensation and is a co-founder and SAB member of Revolution Medicines. All other authors do not have financial or non-financial competing interests.
